跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
STING antagonist
首页
药物
STING antagonist
STING antagonist
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
STING ANTAGONIST COMPOUNDS
EP 4534147 A1
申请人: SULIS THERAPEUTICS APS
优先权: 2023
EP
WO
3 件公开
NANOENCAPSULATED PHARMACEUTICAL COMPOSITION AND USE THEREOF
US 20250108106 A1
申请人: FULGENT GENETICS INC
优先权: 2022
CN
US
2 件公开
ANTAGONIST HETEROCYCLIC COMPOUNDS INVOLVED IN THE CGAS-STING ROUTE
EP 4678234 A1
申请人: CENTRE NAT RECH SCIENT
优先权: 2024
EP
WO
2 件公开
Small molecular inhibitors of sting signaling compositions and methods of use
US 11897888 B1
申请人: BARBER GLEN N
优先权: 2021
US
2 件公开
METHODS AND COMPOSITIONS FOR TREATING B CELL CANCERS
WO 2017011444 A1
申请人: WISTAR INST
优先权: 2015
WO
Combinations of PD-1 antagonists and benzo [b] thiophene STING agonists for cancer treatment
US 11312772 B2
申请人: MERCK SHARP & DOHME
优先权: 2018
US
Methods of treating cancer
CN 114761804 A
申请人: AFORMDEO S A
优先权: 2019
CN
CN 117425475 A
申请人: AFORMDEO S A
优先权: 2020
CN
CN 117320708 A
申请人: AFORMDEO S A
优先权: 2020
CN
CN 117412745 A
申请人: AFORMDEO S A
优先权: 2020
CN
CN 117597117 A
申请人: AFORMDEO S A
优先权: 2020
CN
Dendrimer compositions and methods for drug delivery
CN 115103689 A
申请人: ASHVATA THERAPEUTICS INC
优先权: 2019
CN
Modified mRNA for vaccine development
CN 115210373 A
申请人: BASECLICK GMBH
优先权: 2020
CN
NOVEL XANTHENONE DERIVATIVE
WO 2021200824 A1
申请人: NAT INST BIOMEDICAL INNOVATION HEALTH & NUTRITION
优先权: 2020
WO
第 1 / 2 页
上一页
下一页
药物
反馈